E. Goluszko

发表

E2F3 Is a Mediator of DNA Damage-Induced Apoptosis

G. Lozano, S. Post, Zhenping Chen, 2009, Molecular and Cellular Biology.

ToleranceAcetylcholine Receptor T Cell Epitope Clonal Anergy Involved in Systemic Fas/Fas Ligand Pathway, Apoptosis, and

P. Christadoss, E. Goluszko, C. Deng, 2001 .

Fas/Fas Ligand Pathway, Apoptosis, and Clonal Anergy Involved in Systemic Acetylcholine Receptor T Cell Epitope Tolerance

P. Christadoss, E. Goluszko, C. Deng, 2001 .

Vaccination with Purified Dr Fimbriae Reduces Mortality Associated with Chronic Urinary Tract Infection Due to Escherichia coli Bearing Dr Adhesin

B. Nowicki, S. Nowicki, V. Popov, 2005, Infection and Immunity.

Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis

P. Christadoss, E. Goluszko, M. Poussin, 2002, Journal of Neuroimmunology.

Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein

P. Christadoss, E. Goluszko, 2002, Journal of Neuroimmunology.

Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR

P. Christadoss, E. Goluszko, T. K. Hughes, 2000, Journal of Neuroimmunology.

B7-1 Costimulatory Molecule Is Critical for the Development of Experimental Autoimmune Myasthenia Gravis1

P. Christadoss, E. Goluszko, E. Tüzün, 2003, The Journal of Immunology.

Autoimmune Myasthenia Gravis the Development of Experimental B 7-1 Costimulatory Molecule Is Critical for Premkumar Christadoss

P. Christadoss, E. Goluszko, E. Tüzün, 2003 .

This information is current as Formation and C3 Production Associated with Reduced Germinal Center Myasthenia Gravis in IL-6-Deficient Mice Is Resistance to Experimental Autoimmune

P. Christadoss, E. Goluszko, E. Tüzün, 2013 .

Resistance to Experimental Autoimmune Myasthenia Gravis in IL-6-Deficient Mice Is Associated with Reduced Germinal Center Formation and C3 Production1

P. Christadoss, E. Goluszko, E. Tüzün, 2002, The Journal of Immunology.

Formation and C 3 Production Associated with Reduced Germinal Center Myasthenia Gravis in IL-6-Deficient Mice Is Resistance to Experimental Autoimmune and Premkumar

E. Goluszko, E. Tüzün, Huan Yang, 2002 .

Association of colony variation in Serratia marcescens with the differential expression of protease and type 1 fimbriae.

B. Nowicki, S. Nowicki, E. Goluszko, 1995, FEMS microbiology letters.

HLA-DQ6 transgenic mice resistance to experimental autoimmune myasthenia gravis is linked to reduced acetylcholine receptor-specific IFN-gamma, IL-2 and IL-10 production.

P. Christadoss, C. David, E. Goluszko, 2001, Journal of autoimmunity.

Rad18 is a transcriptional target of E2F3

P. M. Do, L. Varanasi, Luis A. Martinez, 2012, Cell cycle.

TCR gene usage in experimental autoimmune myasthenia gravis pathogenesis. Usage of multiple TCRBV genes in the H-2b strains.

M. Shenoy, P. Christadoss, R. Kaul, 1995, Journal of immunology.

Suppressed clinical experimental autoimmune myasthenia gravis in bm12 mice is linked to reduced intracellular calcium mobilization and IL-10 and IFN-γ release by acetylcholine receptor-specific T cells

P. Christadoss, V. Reyes, E. Goluszko, 2003, Journal of Neuroimmunology.

Genetic Evidence for Involvement of Classical Complement Pathway in Induction of Experimental Autoimmune Myasthenia Gravis 1

S. Higgs, P. Christadoss, E. Goluszko, 2003, The Journal of Immunology.

Experimental Autoimmune Myasthenia Gravis in the Mouse

P. Christadoss, E. Goluszko, E. Tüzün, 2011, Current protocols in immunology.

Experimental Autoimmune Myasthenia Gravis in the Mouse

P. Christadoss, E. Goluszko, E. Tüzün, 2011, Current protocols in immunology.

Role of IL-5 during primary and secondary immune response to acetylcholine receptor

P. Christadoss, E. Goluszko, M. Poussin, 2002, Journal of Neuroimmunology.

Establishment of a mouse model of myasthenia gravis which mimics human myasthenia gravis pathogenesis for immune intervention.

M. Shenoy, P. Christadoss, R. Kaul, 1995, Advances in experimental medicine and biology.

Experimental Autoimmune Myasthenia Gravis Complement Pathway in Induction of Genetic Evidence for Involvement of Classical

P. Christadoss, E. Goluszko, E. Tüzün, 2013 .

Genetic Evidence for Involvement of Classical Complement Pathway in Induction of Experimental Autoimmune Myasthenia Gravis 1

S. Higgs, P. Christadoss, E. Goluszko, 2003, The Journal of Immunology.

Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis

P. Christadoss, E. Goluszko, P. Hjelmström, 2001, Journal of Neuroimmunology.

IFN-α treatment suppresses the development of experimental autoimmune myasthenia gravis

M. Shenoy, P. Christadoss, S. Baron, 1995 .

Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice.

P. Christadoss, C. David, E. Goluszko, 2002, The Journal of clinical investigation.

Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis.

M. Shenoy, P. Christadoss, R. Kaul, 1994, Journal of immunology.

Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis.

P. Christadoss, E. Goluszko, C. Deng, 1997, Journal of immunology.

The pathogenic role of acetylcholine receptor α chain epitope within α146-162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice

M. Shenoy, P. Christadoss, E. Goluszko, 1994 .

Induction of Myasthenia Gravis in HLA Transgenic Mice by Immunization with Human Acetylcholine Receptors

P. Christadoss, C. David, E. Goluszko, 2003, Annals of the New York Academy of Sciences.

Circulating Immune Complexes Augment Severity of Antibody-Mediated Myasthenia Gravis in Hypogammaglobulinemic RIIIS/J Mice1

S. Higgs, P. Christadoss, E. Goluszko, 2004, The Journal of Immunology.

Mice Gravis in Hypogammaglobulinemic RIIIS / J Severity of Antibody-Mediated Myasthenia Circulating Immune Complexes Augment

S. Higgs, P. Christadoss, E. Goluszko, 2004 .

Experimental autoimmune myasthenia gravis in B10.BV8S2 transgenic mice: preferential usage of TCRAV1 gene by lymphocytes responding to acetylcholine receptor.

M. Shenoy, P. Christadoss, R. Kaul, 1997, Journal of Immunology.

Possible Linkage of Myasthenia Gravis Susceptibility in R111 S/J Mice to a Genomic Deletion of T Cell Receptor Vβ Genes

M. Shenoy, P. Christadoss, R. Kaul, 1994 .

The effect of B cell deficiency on the immune response to acetylcholine receptor and the development of experimental autoimmune myasthenia gravis.

P. Christadoss, E. Goluszko, C. Deng, 1998, Clinical immunology and immunopathology.

Effect of MHC class I and CD8 cell deficiency on experimental autoimmune myasthenia gravis pathogenesis.

M. Shenoy, P. Christadoss, R. Kaul, 1994, Journal of immunology.

Cathepsin S Is Required for Murine Autoimmune Myasthenia Gravis Pathogenesis1

P. Christadoss, H. Chapman, E. Goluszko, 2005, The Journal of Immunology.

IFN-α Therapy Is Effective in Suppressing the Clinical Experimental Myasthenia Gravis

P. Christadoss, S. Baron, E. Goluszko, 1996 .

Fas/Fas Ligand Pathway, Apoptosis, and Clonal Anergy Involved in Systemic Acetylcholine Receptor T Cell Epitope Tolerance1

P. Christadoss, E. Goluszko, C. Deng, 2001, The Journal of Immunology.

Short communication Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein

P. Christadoss, E. Goluszko, 2002 .